Robeco Institutional Asset Management B.V. raised its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 62.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 40,986 shares of the pharmaceutical company’s stock after acquiring an additional 15,783 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Vertex Pharmaceuticals were worth $7,540,000 as of its most recent SEC filing.
A number of other institutional investors have also recently modified their holdings of VRTX. Resources Investment Advisors Inc. acquired a new position in Vertex Pharmaceuticals in the 4th quarter valued at $27,000. FTB Advisors Inc. increased its stake in Vertex Pharmaceuticals by 1,618.2% in the 1st quarter. FTB Advisors Inc. now owns 189 shares of the pharmaceutical company’s stock valued at $35,000 after buying an additional 178 shares during the period. We Are One Seven LLC acquired a new position in Vertex Pharmaceuticals in the 4th quarter valued at $32,000. Berman Capital Advisors LLC acquired a new position in Vertex Pharmaceuticals in the 4th quarter valued at $35,000. Finally, Sontag Advisory LLC acquired a new position in Vertex Pharmaceuticals in the 4th quarter valued at $36,000. Institutional investors own 94.92% of the company’s stock.
Several equities analysts have issued reports on the stock. Zacks Investment Research raised shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, January 26th. BidaskClub raised shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, March 16th. Svb Leerink reissued a “market perform” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, March 19th. Leerink Swann lowered shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $185.40 target price on the stock. in a research report on Tuesday, March 19th. They noted that the move was a valuation call. Finally, BMO Capital Markets boosted their target price on shares of Vertex Pharmaceuticals to $234.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 6th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and fifteen have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $203.35.
Vertex Pharmaceuticals stock opened at $166.72 on Thursday. Vertex Pharmaceuticals Incorporated has a 52 week low of $144.07 and a 52 week high of $195.81. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.66 and a current ratio of 3.78. The stock has a market capitalization of $42.74 billion, a P/E ratio of 58.91, a price-to-earnings-growth ratio of 2.39 and a beta of 1.56.
Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Tuesday, April 30th. The pharmaceutical company reported $1.14 EPS for the quarter, topping the consensus estimate of $0.65 by $0.49. Vertex Pharmaceuticals had a net margin of 66.01% and a return on equity of 22.63%. The business had revenue of $857.00 million for the quarter, compared to analyst estimates of $853.00 million. During the same period in the previous year, the firm earned $0.76 EPS. The business’s revenue for the quarter was up 34.3% compared to the same quarter last year. Analysts forecast that Vertex Pharmaceuticals Incorporated will post 3.06 EPS for the current fiscal year.
In other Vertex Pharmaceuticals news, CEO Jeffrey M. Leiden sold 33,058 shares of the company’s stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $175.01, for a total value of $5,785,480.58. Following the transaction, the chief executive officer now directly owns 136,953 shares in the company, valued at approximately $23,968,144.53. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP David Altshuler sold 5,624 shares of the company’s stock in a transaction dated Tuesday, February 19th. The shares were sold at an average price of $187.00, for a total transaction of $1,051,688.00. Following the completion of the transaction, the executive vice president now owns 32,604 shares in the company, valued at $6,096,948. The disclosure for this sale can be found here. Insiders sold a total of 81,705 shares of company stock worth $14,703,196 over the last quarter. Insiders own 0.70% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Robeco Institutional Asset Management B.V. Purchases 15,783 Shares of Vertex Pharmaceuticals Incorporated (VRTX)” was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2019/05/16/robeco-institutional-asset-management-b-v-purchases-15783-shares-of-vertex-pharmaceuticals-incorporated-vrtx.html.
Vertex Pharmaceuticals Profile
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.
Read More: What is net income?
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.